6 Reasons I've Been Aggressively Buying Teva Pharmaceutical Industries
Israeli-based Teva Pharmaceutical Industries (NYSE: TEVA) has had quite a run of bad luck. Like really, really bad luck. Its share price has been cut by roughly three quarters in less than two years, as a confluence of factors have weighed on its core businesses and made its outlook quite murky.
In the company's second-quarter earnings report, which saw Teva slash its dividend by 75% and cut its full-year sales and profit forecast, management noted continuing weakness in the generic-drug pricing environment. As the largest manufacturer of generic drugs, Teva is more directly affected by generic-drug weakness than any other company, and it doesn't look as if this pricing weakness will stabilize in the next couple of quarters.
Image source: Getty Images.
Source: Fool.com
Teva Pharmaceutical Industries Ltd ADR Stock
With 17 Buy predictions and not the single Sell prediction the community is currently very high on Teva Pharmaceutical Industries Ltd ADR.
With a target price of 18 € there is a slightly positive potential of 14.29% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 15.75 €.
